TRIAL DETAIL

Study of XL820 Given Orally Daily to Subjects With Solid Tumors

Drug:
Trial Name:
Study of XL820 Given Orally Daily to Subjects With Solid Tumors
NCT#:
Conditions:
Cancer
Status:
Completed
Phase:
1
Start Date 07/01/2006
Age of Trial (yrs) 18.8
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor
Strategy:
Block KIT
Trial Type:
GIST not specified. GIST patients known to be enrolled.
Other Protocol IDs:
Sponsor:
Patient Contact:
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
2 sites recruiting. Lookup NCT00350831. If using clinicaltrials.gov use 'Focused Search' and 'NCT or Study ID' field. If using cancer .gov use 'Advanced Search' and enter NCT # in 'Protocol ID' field
We understand that the phase II trial for GIST has been "withdrawn".

Trial Links

Trial Results

Drug Information
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
 

Trial Sites

Name
Address
City
State
Zip
Country
195 Little Albany St.
New Brunswick
NJ
08903
USA
7979 Wurzbach Rd.
San Antonio
TX
78229
USA